An interventional study of Active Repetitive Transcranial Magnetic Stimulation and Active Repetitive Transcranial Magnetic Stimulation in Gulf War Illness, Headache and Muscle and Joint Pain, sponsored by Veterans Medical Research Foundation. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Veterans Medical Research Foundation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 326 studies in Headache with a site in United States — 52 open to participants now, 65 under way, 5 of them phase 3. Headache · United States.
Among the 326 studies in Headache with a site in United States, this one is the 77th largest by planned enrollment of the 278 interventional ones that give a count, is one of 18 that started in 2026, is one of 128 with no phase, reaches primary completion later than 59 of the 63 other live ones, and was the 310th registered.
764 studies on the registry are indexed under Headache; 134 are open to participants now.
Browse Headache studies →52 of the 326 studies in Headache with a site in United States are open now. Recruiting first, the newest first:
Salvia BioElectronics · Sites in United States
Ages 22–84
University of Colorado, Denver · Sites in United States
Ages 12–17
Daniel A Tonetti, MD · Sites in United States
Ages 18+
Cortex Neurovascular · Sites in United States
Ages 18–64
Duke University · Sites in United States
Ages 18–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 83 Headache studies recruiting now, 30 (36%) set no upper age limit and 44 (53%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
326 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 56 · Phase 3 54 · Phase 4 37
First in 1994; this study’s year is marked. 18 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 65 across 562 interventional studies indexed under Headache.
Median enrollment 64 across the 278 interventional studies, 129 across the 47 observational. Of the 225 that completed or were terminated, 104 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 326 have an industry lead sponsor. The 10 most frequent:
Veterans Medical Research Foundation is the lead sponsor of 43 studies on the registry; 9 are open to participants now.
Veterans Medical Research Foundation has 4 studies filed under Headache — fewer than ten, so there is no comparison to draw.
21 of the studies in Headache with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06621329Phase 3University of California, DavisTransnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache | 2027-07 |
| NCT07116408Wright State UniversityIntranasal Sphenopalatine Ganglion Blockade for Headaches Following Aneurysmal Subarachnoid Hemorrhage | 2026-11 |
| NCT07950033Life Harmony Energies, Inc.A Study to Evaluate the Effects of the EMF Harmony Products on Health Parameters Associated With EMF Radiation Exposure | 2026-12 |
| NCT07309874Texas Tech University Health Sciences CenterEffect of Ultrasound-Guided Dry Needling Targeting Rectus Capitus Posterior Major on Individuals With Headaches | 2026-12-01 |
| NCT07725198Florida Gulf Coast UniversityImmediate Neuromuscular Responses of the Obliquus Capitis Inferior Following Upper Cervical Manual Therapy | 2027-01-01 |
Add all 21 to your calendar (.ics) → With an account.
Among the 326 studies in Headache with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to create a machine learning algorithm to improve active repetitive transcranial magnetic stimulation (rTMS) treatments for veterans and/or active military personnel by alleviating Gulf War Illness related headaches and body pain (GWI-HAP). This study aims to develop and validate a Support Vector Machine (SVM) model that could replace the trial-and-error process by assessing functional connectivity provided by resting state functional magnetic resonance imaging (rs-fMRI) data to predict the most effective rTMS protocol for each person. All participants will be receiving active rTMS treatment.
The main questions it intends to answer are:
Participants will undergo the following:
This study aims to enroll a total of 140 veterans and/or active military personnel over the 4-year study period at the VA San Diego Healthcare System (VASDHS). Participants will be randomized into receiving treatments at the left DLPFC or left DLPFC and LMC, then placed into predicted respondent or non-respondent groups. They will be assigned to 1 of 4 groups:
Group A: Predicted Respondent at Left DLPFC Group B: Predicted Non-respondent at Left DLPFC Group C: Predicted Respondent at Left DLPFC and LMC Group D: Predicted Non-respondent at Left DLPFC and LMC
Participation in this study will require 15 total visits to the VASDHS over the course of 3-4 months. The visits will be separated in the following phases:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Active Repetitive Transcranial Magnetic Stimulation
Device: Active Repetitive Transcranial Magnetic Stimulation
Device: Active Repetitive Transcranial Magnetic Stimulation
Device: Active Repetitive Transcranial Magnetic Stimulation
rTMS will be administered to the LDLPFC with an active coil.
rTMS will be administered to the LDLPFC with an active coil.
rTMS will be administered to the LDLPFC and LMC with an active coil.
rTMS will be administered to the LDLPFC and LMC with an active coil.
Pain Intensity - Mechanical Visual Analogue Scale (M-VAS)
A scale that ranges from 0 to 10 ("No pain" to "Worst possible pain").
Time frame: From baseline to the end of treatment at 16 weeks
Headache and Pain Log
A personal daily log is used to track the subject's headaches, muscle and joint pain throughout the course of the study based on a range of 0 to 10, with higher scores indicating more severe pain.
Time frame: From enrollment to the end of treatment at 16 weeks
Mood - Hamilton Rating Scale for Depression (HRSD)
This scale is a well-established questionnaire which consists of twenty-one questions and rates the severity of symptoms observed in depression such as low mood, insomnia, agitation, anxiety and weight loss. Only the first 17 items are used for the overall scoring. A score between 14 and 18 represents a moderate form of depression and a score greater than 19 represents severe depression.
Time frame: From baseline to end of treatment at 16 weeks
Pain Severity - Brief Pain Inventory-Short Form (BPI-sf)
This is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the 24-hour period prior to evaluation. The BPI-sf consists of five questions. Four items measure pain on 11-point response scales from 0 to 10 ("No Pain" to "Pain as bad as you can imagine"). Another item, containing 7 sub-questions, evaluates the level of pain interference with daily functioning on 11-point response scales from 0 to 10 ("Does not interfere" to "Completely interferes"). Items 3-6 are summed together for a total average pain severity score.
Time frame: Baseline, 1-week, 1-month, 2-months
Pain Severity - Brief Pain Inventory-Short Form (BPI-sf)
This is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the 24-hour period prior to evaluation. The BPI-sf consists of five questions. Four items measure pain on 11-point response scales from 0 to 10 ("No Pain" to "Pain as bad as you can imagine"). Another item, containing 7 sub-questions, evaluates the level of pain interference with daily functioning on 11-point response scales from 0 to 10 ("Does not interfere" to "Completely interferes"). Items 9A-9G are summed together for a total pain interference score.
Time frame: Baseline, 1-week, 1-month, 2-months
Pain Quality and Intensity - Short Form McGill Pain Questionnaire (SF-MPQ)
This is a self-report questionnaire that allows individuals to describe the quality and intensity of pain they are experiencing. This will be used to assess the sensory and affective aspects of muscle pain. The SF-MPQ consists of fifteen questions; items 1-11 are measured on a 4-point response scale ranging from 0 to 3 ("None" to "Severe"). Items 12-15 include a visual analogue scale (VAS) from "No pain" to "Worst possible pain" and Present Pain Intensity (PPI) ranging from 0 to 5 ("No pain" to "Excruciating") ranking overall pain intensity for a total average muscle pain score. This is calculated via the average VAS scores (0-100) with 0 indicating no pain and 100 equivalent to the worst pain possible.
Time frame: Baseline, 1-week, 1-month, 2-months
Pain Quality and Intensity - Short Form McGill Pain Questionnaire (SF-MPQ)
This is a self-report questionnaire that allows individuals to describe the quality and intensity of pain they are experiencing. This will be used to assess the sensory and affective aspects of joint pain. The SF-MPQ consists of fifteen questions; items 1-11 are measured on a 4-point response scale ranging from 0 to 3 ("None" to "Severe"). Items 12-15 include a visual analogue scale (VAS) from "No pain" to "Worst possible pain" and Present Pain Intensity (PPI) ranging from 0 to 5 ("No pain" to "Excruciating") ranking overall pain intensity for a total average joint pain score. This is calculated via the average VAS scores (0-100) with 0 indicating no pain and 100 equivalent to the worst pain possible.
Time frame: Baseline, 1-week, 1-month, 2-months
Functionality - Revised Fibromyalgia Impact Questionnaire
A questionnaire to evaluate the function, overall impact and symptoms of Fibromyalgia. The 3 categories are calculated by the sum of the scores to produce a total score. Each item ranges from 0-10 and the total score is 0-100 with high scores indicating more severe impact.
Time frame: Baseline, 1-week, 1-month, 2-months
Pain Intensity - New Clinical Fibromyalgia Diagnostic Criteria - Part 1
Patients will be asked to rate the average (over the past week) intensity of muscle pain up to 12 locations of the body. This is calculated by the Widespread Pain Index (WPI) total score ranging from 0 to 19 and a marker visual analogue scale (MVAS) ranging from 0 to 100.
Time frame: Baseline, 1-week, 1-month, 2-months
Pain Severity - Headache Impact Test (HIT-6)
This test measures how impact headaches affect the individual's ability to function in different domains. This six question test evaluates the severity of headache pain from "Never" to "Always" with a total range between 36-78, higher scores indicating greater impact on functionality.
Time frame: Baseline, 1-week, 1-month, 2-months
Pain Severity - Neurobehavioral Symptoms Inventory (NSI)
This twenty-two self-report questionnaire on the severity of each symptom is measured using a 5-point response scale ranging from 0 to 4 ("None - Rarely if ever present; not a problem at all" to "Very Severe - Almost always present and I have been unable to perform at work, school or home due to this problem; I probably cannot function without help"). It asks the subjects to indicate the extent to which each symptom has disturbed them. The total score ranges from 0 to 88 with a higher score indicating very severe symptom disruption.
Time frame: Baseline, 1-week, 1-month, 2-months
Sleep Quality - Pittsburgh Sleep Quality Index (PSQI)
This index has nineteen individual items which are used to generate 7 composite scores on: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The 7 components measure sleep habits and sum together to measure global sleep quality with a high score of 0-21 with a higher score indicating worse sleep quality.
Time frame: Baseline, 1-week, 1-month, 2-months
Sleep Severity - Insomnia Severity Index
This index consists of seven questions that depict the severity of sleep difficulties within the past 2 weeks on a 5-point response scale that rates satisfaction, noticeability, distress, and interference with daily functioning. A score between 15 and 21 suggests moderately severe clinical insomnia. A score of 22 or greater represents severe clinical insomnia.
Time frame: Baseline, 1-week, 1-month, 2-months
Quality of Life - Veteran RAND 36-item Health Survey (VR-36+PCS and MCS)
A patient-reported survey of patient health. It is a measure of health status and quality of life in regards to eight main areas: vitality, physical functioning, bodily pain, health perceptions, physical, emotional, and social role functioning and mental health.
Time frame: Baseline, 1-week, 1-month, 2-months
Multidimensional Fatigue Inventory
A twenty item self-report instrument with 4 categories total designed to measure fatigue level (24-96) with a higher score indicating more severe fatigue.
Time frame: Baseline, 1-week, 1-month, 2-months
Chronic Fatigue Severity Scale
A Likert scale consisting of nine items that assess fatigue severity and functionality. The sum of all questions provides total fatigue level 8-63 with a higher score being more severe. A score over 36 indicates patient may be suffering from fatigue.
Time frame: Baseline, 1-week, 1-month, 2-months
Opiate/Medication Assessment
This assessment evaluates opiate consumption over the duration of the study. Opioids and narcotics are converted to their morphine equivalent value on a daily basis. Values during each measurement period are added up and divided by the number of weeks to determine weekly usage.
Time frame: From the baseline to the end of treatment at 16 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Oct 2029, 43 months after the start.
Of 177 non-industry interventional studies with no phase under Headache, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 39. This study's planned 43 months is above that.
Counting every sponsor, half of 196 studies reached it within 14 months; a quarter within 6 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Veterans Medical Research Foundation